公开(公告)号：EP4438122A2

公开(公告)日：2024-10-02

申请号：EP24195442.9

申请日：2022-04-18

Applicant: Fujian Akeylink Biotechnology Co., Ltd.

Inventor： CHEN, Shuhui ,  YANG, Yaxun ,  ZHANG, Jianchen ,  LI, Peng ,  HE, Haiying ,  WANG, Zheng ,  LI, Jian

IPC: A61P31/14

CPC classification number: A61K31/403 ,  A61P31/14 ,  C07D401/12 ,  C07D403/12 ,  C07K5/06078 ,  C07K5/0606 ,  C07K5/06043 ,  C07K1/003 ,  A61K31/427 ,  A61K31/439 ,  A61K31/407

Abstract: Disclosed are ring-modified proline short peptide compound and the use thereof, and specifically disclosed is a compound represented by formula (X) or a pharmaceutically acceptable salt thereof.

公开(公告)号：EP3256121B1

公开(公告)日：2024-08-07

申请号：EP16704226.6

申请日：2016-02-12

IPC: A61K31/403 ,  A61P29/00 ,  A61P37/02 ,  A61P43/00

CPC classification number: A61K31/403 ,  A61P29/00 ,  A61P37/02 ,  A61P43/00

公开(公告)号：EP4400505A1

公开(公告)日：2024-07-17

申请号：EP22863643.7

申请日：2022-09-02

Applicant: Bivision Pharmaceuticals, Inc

Inventor： YU, Haihua ,  WANG, Eric Yanjun ,  WANG, Kevin Yu

IPC: C07F13/00 ,  C07K5/037 ,  A61K51/04 ,  A61K103/30 ,  A61K103/40 ,  A61K103/00 ,  A61P35/00

CPC classification number: Y02P20/55 ,  A61K31/395 ,  A61K31/397 ,  A61K31/403 ,  A61K31/428 ,  A61K31/438 ,  A61K31/4725 ,  A61K31/555 ,  A61K49/00 ,  A61K51/00 ,  A61K51/04 ,  A61P35/00 ,  C07D257/02 ,  C07D403/06 ,  C07D401/06 ,  C07D417/06 ,  C07F13/00 ,  C07K5/0215

Abstract: A peptide-urea derivative, a pharmaceutical composition containing same and an application thereof are provided, the derivative being as shown in formula I. The derivative can be used for preoperative imaging diagnosis and grading of PSMA-positive prostate cancer, and can also be used for the treatment of various types and stages of prostate cancer, achieving the integration of diagnosis and treatment, and having broad application prospects.

公开(公告)号：EP3411020A1

公开(公告)日：2018-12-12

申请号：EP17747672.8

申请日：2017-01-24

Applicant: Samjin Pharmaceutical Co., Ltd.

Inventor： CHO, Eui Hwan ,  CHOI, Sung-Ju ,  LEE, Sung-Woo ,  SHIN, Hee-Jong ,  KI, Min-Hyo ,  CHOI, Mee-Hwa ,  OH, Tae-Hoon

IPC: A61K9/28 ,  A61K9/48 ,  A61K47/44 ,  A61K31/403

CPC classification number: A61K9/284 ,  A61K9/2866 ,  A61K31/403

Abstract: Disclosed is an immediate-release carvedilol formulation, which is configured such that a coating layer including a polymer, wax, fatty acid and/or fatty acid ester is formed on the surface thereof. This formulation has improved madescent, and thus can exhibit high stability, in which the initial appearance of the formulation can be maintained without cracking or breaking even under storage conditions at high relative humidity.

公开(公告)号：EP3405183A1

公开(公告)日：2018-11-28

申请号：EP17741793.8

申请日：2017-01-13

Applicant: Arisan Therapeutics Inc.

Inventor： PLEWE, Michael ,  BROWN, Eric ,  GANTLA, Vidyasagar ,  HENKEL, Gregory ,  MCCORMACK, Kenneth ,  SOKOLOVA, Nadezda

IPC: A61K31/015 ,  A61K31/135 ,  A61K31/165 ,  C07C13/28 ,  C07C13/54 ,  C07C13/573

CPC classification number: C07D295/32 ,  A61K31/165 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/407 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4465 ,  A61K31/4545 ,  A61K31/495 ,  A61K31/496 ,  A61K31/4995 ,  A61K31/5375 ,  A61K31/551 ,  C07C217/58 ,  C07C233/41 ,  C07C233/43 ,  C07C233/62 ,  C07C235/40 ,  C07C237/24 ,  C07C275/26 ,  C07C2601/14 ,  C07C2603/74 ,  C07D205/04 ,  C07D205/12 ,  C07D209/94 ,  C07D211/34 ,  C07D211/56 ,  C07D211/58 ,  C07D211/60 ,  C07D211/62 ,  C07D213/74 ,  C07D213/75 ,  C07D213/82 ,  C07D233/64 ,  C07D243/08 ,  C07D295/03 ,  C07D295/088 ,  C07D295/13 ,  C07D295/185 ,  C07D295/192 ,  C07D295/26 ,  C07D451/04 ,  C07D453/02 ,  C07D487/04 ,  C07D487/06 ,  C07D487/10

Abstract: Compounds of structural Formula (I) were developed for the treatment of infections by filoviruses including Ebolavirus and Marburgvirus.

公开(公告)号：EP3388062A1

公开(公告)日：2018-10-17

申请号：EP18175031.6

申请日：2013-09-04

Applicant: Pharnext

Inventor： COHEN, Daniel ,  NABIROCHKIN, Serguei ,  CHUMAKOV, Ilya

IPC: A61K31/24 ,  A61K31/44 ,  A61K31/421 ,  A61K31/185

CPC classification number: A61K31/519 ,  A61K31/13 ,  A61K31/135 ,  A61K31/137 ,  A61K31/138 ,  A61K31/155 ,  A61K31/165 ,  A61K31/185 ,  A61K31/192 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/216 ,  A61K31/24 ,  A61K31/27 ,  A61K31/343 ,  A61K31/353 ,  A61K31/403 ,  A61K31/4045 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/42 ,  A61K31/421 ,  A61K31/428 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4422 ,  A61K31/445 ,  A61K31/4458 ,  A61K31/4525 ,  A61K31/48 ,  A61K31/485 ,  A61K31/505 ,  A61K31/506 ,  A61K31/55 ,  A61K31/551 ,  A61K31/5513 ,  A61K31/64 ,  A61K45/06 ,  A61K2300/00

Abstract: The present invention relates to compositions and methods for the treatment of Parkinson's disease and related disorders. More specifically, the present invention relates to novel combinatorial therapies of Parkinson's disease and related disorders targeting the alpha-synuclein aggregation network. In particular, the invention relates to compounds which, alone or in combination(s), can effectively protect neuronal cells from alpha-synuclein aggregates. The invention also relates to methods of producing a drug or a drug combination for treating Parkinson's disease and to methods of treating Parkinson's disease or a related disorder.

公开(公告)号：EP2776066B1

公开(公告)日：2018-09-19

申请号：EP12847546.4

申请日：2012-11-06

Applicant: Université Laval

Inventor： FRENETTE, Jérôme ,  PENNINGER, Josef

IPC: A61K31/137 ,  A61K31/167 ,  A61K31/401 ,  A61K31/403 ,  A61K31/405 ,  A61K31/417 ,  A61K31/472 ,  A61K31/55 ,  A61K31/568 ,  A61K31/573 ,  A61K31/675 ,  A61K31/7105 ,  A61K38/17 ,  A61K38/27 ,  A61K38/30 ,  A61K45/06 ,  G01N33/68 ,  A61P21/00

CPC classification number: A61K39/3955 ,  A61K31/137 ,  A61K31/167 ,  A61K31/401 ,  A61K31/403 ,  A61K31/405 ,  A61K31/417 ,  A61K31/472 ,  A61K31/55 ,  A61K31/568 ,  A61K31/573 ,  A61K31/675 ,  A61K31/7105 ,  A61K38/1793 ,  A61K38/27 ,  A61K38/30 ,  A61K45/06 ,  C07K16/2875 ,  C12N15/1136 ,  G01N33/6863 ,  G01N2333/7151 ,  G01N2800/2878 ,  A61K2300/00

Abstract: The present invention relates to uses and methods comprising one or more RANK/RANKL antagonists or of a pharmaceutical composition comprising one or more RANK/RANKL antagonists and a pharmaceutically acceptable carrier for treating neuromuscular disorders, non-genetic myopathies, or genetic myopathies; maintaining and/or preserving the excitation:contraction:relaxation coupling; reducing loss of muscle strength associated with neuromuscular disorders, non-genetic myopathies or genetic myopathies; reducing the loss of muscular strength associated with skeletal or cardiac muscle disuse, diseases and aging; or regulating skeletal or cardiac muscle disuse, diseases and/or aging in a patient in need thereof. The present invention also relates to combinations and compositions comprising one or more RANK/RANKL antagonists and to methods for identifying candidate compounds.

公开(公告)号：EP3367890A1

公开(公告)日：2018-09-05

申请号：EP16860690.3

申请日：2016-10-26

Applicant: Immunolight, LLC. ,  Duke University

Inventor： OLDHAM, Mark ,  ADAMSON, Justus ,  DEWHIRST, Mark, W. ,  YOON, Paul ,  WALDER, Harold ,  BOURKE, Frederic, A. ,  FATHI, Zakaryae ,  BEYER, Wayne, F.

IPC: A61B5/00 ,  A61K33/02 ,  A61K41/00 ,  A61K49/04 ,  A61M36/02 ,  A61N5/06 ,  A61N5/10

CPC classification number: A61K41/0066 ,  A61K31/352 ,  A61K31/403 ,  A61K31/409 ,  A61K31/426 ,  A61K31/47 ,  A61K31/525 ,  A61K31/655 ,  A61K33/02 ,  A61K33/24 ,  A61K2300/00 ,  A61N5/062 ,  A61N5/0624 ,  A61N5/10 ,  A61N2005/065 ,  A61N2005/1095 ,  A61N2005/1098 ,  B82Y5/00 ,  Y02A50/393

Abstract: A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.

公开(公告)号：EP3359156A2

公开(公告)日：2018-08-15

申请号：EP16853180.4

申请日：2016-10-07

Applicant: Steerlife India Private Limited

Inventor： PADMANABHAN, Babu ,  SEN, Himadri ,  BHUSHAN, Indu ,  KULKARNI, Vijay ,  SHETTY, Rakshith ,  GURRAM, Aravind Kumar

IPC: A61K31/4985 ,  A61K31/40 ,  A61K31/506 ,  A61K9/20

CPC classification number: A61K31/522 ,  A61K9/0007 ,  A61K9/2018 ,  A61K31/40 ,  A61K31/403 ,  A61K31/4985 ,  A61K31/515

Abstract: A rapidly disintegrating tablet comprising a therapeutically effective amount of a DPP- IV inhibitor and an acid-base couple having mineral content below the daily intake limits is disclosed. The rapidly disintegrating tablet has a sodium content less than 10 mg and a potassium content less than 15 mg. A process for preparation of the rapidly disintegrating tablet comprising the DPP-IV inhibitor is also disclosed.

公开(公告)号：EP2855458B1

公开(公告)日：2018-08-08

申请号：EP13722971.2

申请日：2013-05-10

Applicant: Reset Therapeutics, Inc.

Inventor： BERSOT, Ross ,  HUMPHRIES, Paul

IPC: C07D403/12 ,  C07D405/14 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/06 ,  C07D493/08 ,  C07D209/86 ,  C07D209/88 ,  A61K31/403 ,  A61P3/00 ,  A61P25/00 ,  A61K45/06 ,  A61K31/4155 ,  A61K31/541 ,  A61K31/549 ,  A61K31/404 ,  G01N33/68

CPC classification number: A61K31/549 ,  A61K31/403 ,  A61K31/404 ,  A61K31/4155 ,  A61K31/427 ,  A61K31/428 ,  A61K31/454 ,  A61K31/541 ,  A61K31/5415 ,  A61K45/06 ,  C07D209/86 ,  C07D209/88 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/12 ,  C07D417/06 ,  C07D493/08 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2800/52

Abstract: The subject matter herein is directed to carbazole-containing sulfonamide derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, F, G, H, a, and b are accordingly described. Also provided are pharmaceutical compositions comprising the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, obesity, metabolic syndrome, Cushing's syndrome, and glaucoma.